Abstract:Abstract The MDM2 oncogene is amplified and/or overexpressed in many human cancers, including breast cancer, and it has been suggested as a molecular target for treating human cancers. MDM2 is a major negative regulator of tumor suppressor p53. Most MDM2 inhibitors under development are targeting the MDM2-p53 binding, and have little or no effects on cancers without functional p53, such as advanced breast cancer. Therefore, new strategies to target MDM2 are desirable. The present study was designed to develop a new class of MDM2 inhibitors that exert anti-breast cancer activity, regardless of p53 status in the cancers. The selective MDM2 inhibitors were discovered by a computational structure-based screening, yielding a lead compound, termed JapA. Fluorescence polarization (FP)-based binding assay and cellular thermal shift assay were performed to determine the binding between MDM2 and JapA. Its cytotoxicity was initially evaluated in breast cancer cell lines (MCF-7, MCF-7/p53−/−, MDA-MB-231, and MDA-MB-468) and normal human breast cells (MCF-10A). Its anti-breast cancer activities were further assessed in in vitro and in vivo MCF-7 and MDA-MB-231 models. The molecular mechanisms for its targeting effects on MDM2 were elucidated in various cell models in vitro and in vivo. We further found that JapA selectively inhibited breast cancer cell growth, decreased cell proliferation, and induced G2/M phase arrest and apoptosis in breast cancer cells through an MDM2-dependent mechanism, regardless of p53 status. In MCF-7 and MDA-MB-231 xenograft models, JapA inhibited MDM2 and suppressed tumor growth and lung metastasis in a dose-dependent manner, without host toxicity. Furthermore, JapA directly bound to MDM2 protein and reduced MDM2 levels in cancer cells in vitro and in vivo by promoting MDM2 protein degradation and inhibiting MDM2 transcription, which is distinct from the existing MDM2 inhibitors. In conclusion, JapA represents a new class of MDM2 inhibitor that exerts its anticancer activity through directly down-regulating MDM2, and might be developed as a novel cancer therapeutic agent. (Supported by the NIH R01 CA112029, R01 CA121211, and R01 CA186662) Citation Format: Jiang-Jiang Qin, Wei Wang, Sukesh Voruganti, Ruiwen Zhang. A novel MDM2 inhibitor suppresses breast cancer growth and metastasis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2433. doi:10.1158/1538-7445.AM2015-2433

Inulanolide A As A New Dual Inhibitor of Nfat1-Mdm2 Pathway for Breast Cancer Therapy

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of P53 and Androgen

Abstract 4863: Targeting the NFAT1-MDM2-MDMX Network for Prostate Cancer Therapy

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

[A Study on the Effect of Tanshinone II A Against Human Breast Cancer in Vivo].

Identification of Lineariifolianoid A As a Novel Dual NFAT1 and MDM2 Inhibitor for Human Cancer Therapy

Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.

Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.

Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.

Discovery And Characterization Of Dual Inhibitors Of Mdm2 And Nfat1 For Pancreatic Cancer Therapy

Dual Inhibition of Ornithine Decarboxylase and A1 Adenosine Receptor Efficiently Suppresses Breast Tumor Cells

Abstract 2433: A Novel MDM2 Inhibitor Suppresses Breast Cancer Growth and Metastasis

Abstract 2434: the Anticancer Activity of Japonicone A is Mediated by Inhibiting NFAT1-MDM2 Pathway

Effect of A Small-Molecule Mdm2/Mdmx Inhibitor on Cell Cycle Arrest and Apoptosis in Breast Cancer Cells.

Discovery of Novel PI3K/CDK2 Dual Inhibitor Based on 7-Azaindole Derivatives As a Promising Strategy for Triple-Negative Breast Cancer Therapy

Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer.

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

The Pyrido[b]indole MDM2 Inhibitor SP-141 Exerts Potent Therapeutic Effects in Breast Cancer Models.

Synergistic Effects of Anlotinib and DDP Synergy in Breast Cancer Treatment: Inhibiting of Cell Growth and Migration, and Augmenting Apoptosis and Autophagy Via Modulation of the VEGF/JAK2/STAT3 Axis

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer